CNTB
Connect Biopharma Holdings Limited
Healthcare — Biotechnology
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Strong Buy
1.1 / 5
7 analysts
$0.98
$-0.12 (-10.94%)
Target:
$7.00
(614.5%)
Price History
52-Week Range
Sign in to add CNTB to a watchlist or set price alerts.
Fundamentals
| Market Cap | $150.48M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.87 |
| EPS (TTM) | $-1.15 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -102.94% |
| Debt/Equity | 1.63 |
| Recommendation | Strong Buy 1.1 |
| Analyst Target | $7.00 |
| Analysts | 7 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 68.2 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.82 |
| 52-Week Low | $1.05 |
| 50-Day Avg | $2.32 |
| 200-Day Avg | $2.34 |
| Avg Volume | 698.5K |
| Volume | $2.67M |
Performance Analysis
BULLISHCNTB shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($1.05), which could present a value opportunity.
+
RSI at 68.2 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Wall Street consensus is "Strong Buy" from 7 analysts.
+
Average analyst target of $7.00 implies 614.5% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report